Journal of Clinical and Experimental Hepatology最新文献

{"title":"Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer","authors":"Nimisha ,&nbsp;Sundeep S. Saluja ,&nbsp;Abhay K. Sharma ,&nbsp;Phani K. Nekarakanti ,&nbsp;Apurva ,&nbsp;Arun Kumar ,&nbsp;Ejaj Ahmad ,&nbsp;Syed A. Husain","doi":"10.1016/j.jceh.2024.101410","DOIUrl":"10.1016/j.jceh.2024.101410","url":null,"abstract":"<div><h3>Background</h3><p>Gallbladder cancer (GBC) is a biologically aggressive malignancy requiring appropriate biomarkers to improve its outcome. Role of ABC transporters (ABCB1 and ABCG2) has been linked to cancer aggressiveness, tumorigenesis and multidrug resistance. Herein, we studied the prognostic implication of ABCB1 and ABCG2 in GBC.</p></div><div><h3>Methods</h3><p>Fresh tissue (tumour &amp; normal) samples collected from 54 patients who underwent R0 resection, were analysed for mRNA and protein expression of ABCB1 and ABCG2 by quantitative Real-Time PCR and western blotting, respectively, in this prospective study. The molecular findings were correlated with clinical-pathological parameters using χ2 and fisher exact test. The molecular changes in ABCB1 and ABCG2 were analysed for predicting overall survival (OS), disease-free survival (DFS) and response to chemotherapy using Kaplan–Meier log-rank test and Cox regression multivariate analysis.</p></div><div><h3>Results</h3><p>The mean age of the cohort was 50 ± 13.2 with 26 (48.1%) in patients having early stage gallbladder cancer (GBC). Over-expression of ABCB1 and ABCG2 was noted in 32/54 (59%) and 40/54 (74%) cases, respectively. The protein expression of ABCB1(P-glycoprotein) and ABCG2 (BCRP) was higher in 27/54 (50%) and 37/54 (59%) cases, respectively. The mean OS and DFS was 20.7 ± 11.5 and 19.3 ± 12.2 months at median follow-up of 24 months. The TNM stage, lymph node metastasis, and presence of gallstone were significant factors for predicting OS and DFS on multivariate analysis. Both ABCB1 and ABCG2 did not show any significant correlation with OS and DFS with similar incidences of late death and recurrence among over-expression and down-expression. Sub-group comparison suggests that change in expression pattern of ABCB1 and ABCG2 may not affect response to chemotherapy in GBC.</p></div><div><h3>Conclusion</h3><p>Altered expression of ABCB1 and ABCG2 may not be a useful prognostic marker for survival or response to chemotherapy in GBC. Presently, histo-pathological characteristics and associated gallstones are the important predictors for survival and recurrence in GBC.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140786703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatogenous Diabetes as Compared to Type-2 Diabetes Mellitus and Non-diabetes in Patients With Liver Cirrhosis: Magnitude, Characteristics, and Implications","authors":"Tanmoy Maji ,&nbsp;Mala Mahto ,&nbsp;Sudhir Kumar ,&nbsp;Utpal Anand ,&nbsp;Rajeev N. Priyadarshi ,&nbsp;Rahul Arya ,&nbsp;Ramesh Kumar","doi":"10.1016/j.jceh.2024.101411","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.101411","url":null,"abstract":"<div><h3>Aim</h3><p>Hepatogenous diabetes (HD) is frequently underestimated among cirrhosis patients. The current study assessed the magnitude, clinical characteristics, and implications of HD in cirrhosis patients as compared to the patients with type-2 diabetes mellitus (T2DM) and non-diabetes (ND) cirrhosis.</p></div><div><h3>Methods</h3><p>In a prospective observational study, 338 consecutive eligible cirrhosis patients were screened for diabetes mellitus. A 2-hour oral glucose tolerance test (OGTT) was used to detect HD. The clinical characteristics, complications, and outcomes were ascertained and compared amongst HD, T2DM, and ND patients.</p></div><div><h3>Results</h3><p>In the final study cohort of 316 patients, the proportion of HD, T2DM, and ND was 22.5% (n = 71), 26.3% (n = 83), and 51.3% (n = 162), respectively. HD was the predominant form of diabetes (68.9%) in Child–Pugh class-C cirrhosis. The majority (73%) of HD patients had abnormal OGTT without fasting hyperglycaemia. A lower cut-off of 98.5 mg/dl for fasting blood glucose had a modest sensitivity (72%) and specificity (75%) for predicting HD. In comparison to T2DM patients, HD patients were younger, leaner, and had more advanced cirrhosis. In comparison to ND patients, HD patients were leaner but had higher glycemic indices, serum cholesterol, and arterial ammonia levels. During a median follow-up period of 12 (03–21) months, the frequency of hepatic encephalopathy and variceal haemorrhage were higher in HD and T2DM patients compared to that in the ND group.</p></div><div><h3>Conclusions</h3><p>HD is prevalent in about one fifth of cirrhosis patients. It differs from T2DM and ND in a number of ways, and has association with complications of cirrhosis.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adipokine (adiponectin-rs1501299) Gene Variant and Patient Characteristics in Relation to Metabolic-associated Fatty Liver Disease","authors":"Amal A. Mohamed ,&nbsp;Soha Hassanin ,&nbsp;Ahmed A. Mohamed ,&nbsp;Dalia Zaafar ,&nbsp;Rasha Mohamed ,&nbsp;Mohamed B. Hassan ,&nbsp;Al-Shaymaa A. Hassanin ,&nbsp;Eman Alsayed Abouahmad ,&nbsp;Mohamed A. Sakr ,&nbsp;Soha M. Abd el salam ,&nbsp;Reem A.M. Abdelghafour ,&nbsp;Nashwa M. Muharram ,&nbsp;Marwa K. Darwish ,&nbsp;Saadia faried ,&nbsp;Karmia Nasraldin ,&nbsp;Wael Hafez","doi":"10.1016/j.jceh.2024.101409","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.101409","url":null,"abstract":"<div><h3>Background</h3><p>Several genetic and metabolic variables, most notably the variation in the adipokine gene rs1501298, have been linked to metabolic-associated fatty liver disease etiopathogenesis (MAFLD). Liver biopsy, the gold standard for diagnosing MAFLD, is an invasive procedure; therefore, alternative diagnostic methods are required. Consequently, the integration of these metabolic variables with some of the patients’ characteristics may facilitate the development of noninvasive diagnostic methods that aid in the early detection of MAFLD, identification of at-risk individuals and planning of management strategies.</p></div><div><h3>Methods</h3><p>This study included 224 Egyptians (107 healthy individuals and 117 MAFLD patients). Age, sex, BMI, clinical and laboratory characteristics, and rs1501299 adipokine gene polymorphisms were examined. The rs1501299 variant, insulin resistance, hypertension, obesity, blood pressure, lipid profile, hemoglobin A1C level, and hepatic fibrosis predictors were evaluated for MAFLD risk. The feasibility and effectiveness of developing non-invasive MAFLD diagnostic models will be investigated.</p></div><div><h3>Results</h3><p>The +276G/T (rs1501299) polymorphism (GG vs GT/TT) was linked with MAFLD (OR: 0.43, CI: 0.26–0.69, <em>P</em> = 0.002). The GG variants had lower MAFLD rates than those of the GT and TT variants. In addition to altered lipid profiles, patients with MAFLD showed increased gamma-glutamyl transferase levels (GGT: 56 IU/L vs. 36 IU/L). Genetic diversity also affects the accuracy of hepatic fibrosis and steatosis prediction. Hepatic fibrosis and steatosis predictors had receiver operating characteristic (ROC) AUCs of 0.529%, 0.846%, and 0.700–0.825%, respectively. We examined a diagnostic model based on these variables and demonstrated its effectiveness.</p></div><div><h3>Conclusion</h3><p>The Adipokine variant rs1501299 increased the risk of MAFLD. Identifying and genotyping this variation and other metabolic variables allow for a noninvasive diagnostic model for early MAFLD diagnosis and identification of those at risk. This study illuminates the prevention and management of MAFLD. Further research with more participants is needed to verify these models and to prove their MAFLD diagnostic efficacy.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140649610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease","authors":"Joe F. Mathew ,&nbsp;Charles Panackel ,&nbsp;Mathew Jacob ,&nbsp;Ganesh Ramesh ,&nbsp;Nita John","doi":"10.1016/j.jceh.2024.101407","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.101407","url":null,"abstract":"<div><h3>Introduction</h3><p>Liver biopsy is the gold standard for diagnosing and staging non-alcoholic fatty liver disease (NAFLD), but liver biopsy has its limitations. Non-invasive tests (NITs) eliminate many of the drawbacks of liver biopsy. We did a retrospective observational study to validate the NAFLD Fibrosis Score (NFS score) and Fibrosis Score 4 (FIB-4 index) against the gold standard liver biopsy in a cohort of South Indian patients with NAFLD.</p></div><div><h3>Aims</h3><p>The aim of this study was to validate the diagnostic accuracy of non-invasive fibrosis scoring systems (FIB-4 index and NFS), compared to that of liver histology, to predict AF in a cohort of south Indian patients with NAFLD.</p></div><div><h3>Material and methods</h3><p>A retrospective observational analytical study of patients who had a liver biopsy with a diagnosis of NAFLD and had all the data for aetiology assessment and NIT calculation within 4 weeks of biopsy were included in the study. On liver biopsy, NAFLD was scored as per NIH's NASH committee grading system. NFS and FIB-4 index were calculated, and scores more than 0.676 and 2.67, respectively, were taken as the cut-off to predict advanced fibrosis (AF). The sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve for NFS score and FIB-4 score to diagnose AF were calculated.</p></div><div><h3>Results</h3><p>A total of 147 patients were included in the study. Of these, 56 (38.1%) patients had AF (Stage 3, 4). Patients with AF were more likely to be older and have diabetes mellitus (DM). Patients with AF had lower platelet count, higher aspartate aminotransferase (AST), lower albumin, and higher AST/alanine aminotransferase ratio. An NFS of &gt;0.676 had a sensitivity of 68% and specificity of 100%, and an FIB-4 index of &gt;2.67 had a sensitivity of 67% and specificity of 95.6 % in diagnosing AF in our study.</p></div><div><h3>Conclusion</h3><p>The non-invasive scoring systems NFS and FIB-4 index can be used as a bedside tool for diagnosing liver fibrosis in NAFLD allowing liver biopsy to be used in a more targeted manner for patients diagnosed with AF on NITs.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140645632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Transplantation for Dengue-induced Acute Liver Failure","authors":"Akila Rajakumar,&nbsp;Prateek Gupta,&nbsp;Ashwin Rammohan,&nbsp;Vidya Devarajan,&nbsp;Dinesh Jothimani,&nbsp;Naresh Shanmugam,&nbsp;Ilankumaran Kaliamoorthy,&nbsp;Mohamed Rela","doi":"10.1016/j.jceh.2024.101405","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.101405","url":null,"abstract":"<div><p>Although liver involvement has been observed in over two-third cases of dengue viral infection, less than 1% cases progress to dengue-related acute liver failure (D-ALF). Various aspects of management of this disease remain debated including the need and timing of liver transplantation (LT). Moreover, the outcomes of LT for D-ALF have been suboptimal. We present four contrasting cases of D-ALF, two managed with LT and the other two conservatively to highlight the management dilemmas concerning LT in D-ALF. Based on our 4 cases, we would consider dengue shock syndrome, multisystem involvement and neurological deficit not completely accounted for by the ALF as potential contraindications for LT. These would need to be revisited on a case-to-case basis till larger studies define objective selection criteria for LT in D-ALF.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140618205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult Hepatic Langerhans Cell Histiocytosis: Report of Two Cases With Different Clinico-pathological Manifestations","authors":"Gunjangeet Kaur,&nbsp;Abhirup Chatterjee,&nbsp;Saikat Mitra,&nbsp;Vandit Desai,&nbsp;Gaurav Prakash,&nbsp;Pankaj Gupta,&nbsp;Kirti Gupta,&nbsp;Pankaj Malhotra,&nbsp;Ajay Duseja,&nbsp;Suvradeep Mitra,&nbsp;Jayanta Samanta","doi":"10.1016/j.jceh.2024.101406","DOIUrl":"10.1016/j.jceh.2024.101406","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140399766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-relation of Portal Vein Tumour Thrombus Response With Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma","authors":"Debnarayan Dutta ,&nbsp;Sreenija Yarlagadda ,&nbsp;Sruthi Kalavagunta ,&nbsp;Haridas Nair ,&nbsp;Ajay Sasidharan ,&nbsp;Sathish Kumar Nimmya ,&nbsp;Rajesh Kannan ,&nbsp;Shibu George ,&nbsp;Annex Edappattu ,&nbsp;Nikhil K. Haridas ,&nbsp;Wesley M. Jose ,&nbsp;Pavithran Keechilat ,&nbsp;Arun Valsan ,&nbsp;Anoop Koshy ,&nbsp;Rajesh Gopalakrishna ,&nbsp;Shine Sadasivan ,&nbsp;Unnikrishnan Gopalakrishnan ,&nbsp;Dinesh Balakrishnan ,&nbsp;Othiyil Vayoth Sudheer ,&nbsp;Sudhindran Surendran","doi":"10.1016/j.jceh.2024.101404","DOIUrl":"10.1016/j.jceh.2024.101404","url":null,"abstract":"<div><h3>Background/aims</h3><p>The aim of this study was to prospectively evaluate stereotactic body radiotherapy (SBRT) with robotic radiosurgery in hepatocellular carcinoma patients with macrovascular invasion (HCC-PVT).</p></div><div><h3>Materials and methods</h3><p>Patients with inoperable HCC-PVT, good performance score (PS0-1) and preserved liver function [up to Child-Pugh (CP) B7] were accrued after ethical and scientific committee approval [Clinical trial registry-India (CTRI): 2022/01/050234] for treatment on robotic radiosurgery (M6) and planned with Multiplan (iDMS V2.0). Triple-phase contrast computed tomography (CT) scan was performed for contouring, and gross tumour volume (GTV) included contrast-enhancing mass within main portal vein and adjacent parenchymal disease. Dose prescription was as per risk stratification protocol (22–50 Gy in 5 fractions) while achieving the constraints of mean liver dose &lt;15 Gy, 800 cc liver &lt;8 Gy and the duodenum max of &lt;24 Gy). Response assessment was done at 2 months’ follow-up for recanalization. Patient- and treatment-related factors were evaluated for influence in survival function.</p></div><div><h3>Results</h3><p>Between Jan 2017 and May 2022, 318 consecutive HCC with PVT patients were screened and 219 patients were accrued [male 92%, CP score: 5–7 90%, mean age: 63 years (38–85 yrs), Cancer of the Liver Italian Program &lt;3: 84 (40%), 3–6117 (56%), infective aetiology 9.5%, performance status (PS): 0–37%; 1–56%]. Among 209 consecutive patients accrued for SBRT treatment (10 patients were excluded after accrual due to ascites and decompensation), 139 were evaluable for response assessment (&gt;2 mo follow-up). At mean follow-up of 12.21 months (standard deviation: 10.66), 88 (63%) patients expired and 51 (36%) were alive. Eighty-two (59%) patients had recanalization of PVT (response), 57 (41%) patients did not recanalize and 28 (17%) had progressive/metastatic disease prior to response evaluation (&lt;2 months). Mean overall survival (OS) in responders and non-responders were 18.4 [standard error (SE): 2.52] and 9.34 month (SE 0.81), respectively (<em>P</em> &lt; 0.001). Mean survival in patients with PS0, PS1 and PS2 were 17, 11.7 and 9.7 months (<em>P</em> = 0.019), respectively. OS in partial recanalization, bland thrombus and complete recanalization was 12.4, 14.1 and 30.3 months, respectively (<em>P</em>-0.002). Adjuvant sorafenib, Barcelona Clinic Liver Classification stage, gender, age and RT dose did not influence response to treatment. Recanalization rate was higher in good PS patients (<em>P</em>-0.019). OS in patients with response to treatment, in those with no response to treatment, in those who are fit but not accrued and in those who are not suitable were 18.4, 9.34, 5.9 and 2.6 months, respectively (<em>P</em>-&lt;0.001). Thirty-six of 139 patients (24%) had radiation-induced liver disease (RILD) [10 (7.2%) had classic RILD &amp; 26 (19%) had non-classic RILD]. Derange","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140398729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Selection for Living Donor Liver Transplantation in Acute-on-chronic Liver Failure","authors":"Abu Bakar H. Bhatti ,&nbsp;Syeda F. Qasim ,&nbsp;Zamrood Zamrood ,&nbsp;Shahzad Riyaz ,&nbsp;Nusrat Y. Khan ,&nbsp;Haseeb H. Zia ,&nbsp;Muslim Atiq","doi":"10.1016/j.jceh.2024.101403","DOIUrl":"10.1016/j.jceh.2024.101403","url":null,"abstract":"<div><h3>Background and objectives</h3><p>Acute-on-chronic liver failure (ACLF) is associated with high short-term mortality without liver transplantation (LT). The selection criteria for LT in these patients are not well defined. The objective of this study was to determine factors associated with post-transplant survival in ACLF.</p></div><div><h3>Methods</h3><p>This was a single-center retrospective study of patients who underwent living donor liver transplantation (LDLT) for ACLF between 2012 and 2022. Out of 1093 transplants, 110 patients had underlying ACLF, based on the European Association for the Study of the Liver-Chronic Liver Failure Consortium (EASL-CLIF) criteria. We looked at factors associated with 1-year posttransplant survival.</p></div><div><h3>Results</h3><p>The median model for end-stage liver disease (MELD) score was 33.5 (31–38), and the 1-year posttransplant survival was 72%. Six risk factors were associated with posttransplant survival, namely, body mass index &gt; 30 kg/m² [HR, 4.4; 95% CI, 1.8–10.7], platelet count &lt; 66,000/μl [HR, 2.91; CI,1.2–6.6], poor response to medical treatment [HR, 2.6; CI, 1.1–5.7], drug-resistant bacterial or fungal cultures [HR, 4.2; CI, 1.4–12.4], serum creatinine &gt; 2.5 mg/dl [HR, 3.4; CI, 1.5–7.7], and graft-to-recipient weight ratio &lt; 0.7 [HR, 4.8; CI, 1.4–16.3]. The 1-year post-transplant survival was 84% in patients with 0–2 risk factors (n = 89) and was 6% with 3 risk factors (n = 15) (<em>P</em> &lt; 0.001). For 1-year posttransplant survival, the area under curve (AUC) for the current model was 0.8 (0.69–0.9). The AUC for CLIF-ACLF, Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA), and EASL-CLIF ACLF grades was &lt; 0.5.</p></div><div><h3>Conclusion</h3><p>In LT for ACLF, acceptable survival can be achieved when less than three high-risk factors are present.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140405755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Hepatic Stellate Cells and the Gas6/Axl Axis in Liver Fibrosis and Hepatocellular Carcinoma","authors":"Mohammad Haris Ali,&nbsp;Muhammad Talha,&nbsp;Syed A.S. Hussain","doi":"10.1016/j.jceh.2024.101400","DOIUrl":"10.1016/j.jceh.2024.101400","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140269155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-induced Liver Injury from Hormonal and Non-hormonal Therapies: Insights from a Large Case Series","authors":"Raj Vuppalanchi,&nbsp;Naga Chalasani","doi":"10.1016/j.jceh.2024.101401","DOIUrl":"10.1016/j.jceh.2024.101401","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140279214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}